ABT-737 是一种选择性的 Bcl-2 家族蛋白抑制剂，能够有效抑制 Bcl-2、Bcl-xL 和 Bcl-w 的活性，IC50 值分别为 30.3 nM、78.7 nM 和 197.8 nM。ABT-737 主要用于研究细胞凋亡、抗癌治疗和增强肿瘤对化疗药物的敏感性。

Navitoclax (ABT-263) 是一种口服有效的 Bcl-2 抑制剂，可与多种 Bcl-2 家族蛋白结合，Ki 值小于 1 nM。

TW-37 is a nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM, respectively.

AT101 acetic acid, the R-(-) enantiomer of gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM.

Sabutoclax is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

BH3I-1 is an inhibitor of Bcl-xL with IC50 of 293.95 μM.

A1331852 is a potent and selective BCL-XL inhibitor and may be useful in the treatment of cancer, immune and autoimmune diseases.

Gambogic acid activates caspases with EC50 of 0.78-1.64 μM and competitively inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50 of 1.47, 1.21, 2.02, 0.66, 1.06 and 0.79 μM, respectively.